Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 30, 2022
Data Byte
Assessing an expanse of ALS targets
Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Jun 26, 2019
Distillery Therapeutics
miR-17-92 gene therapy for ALS associated with SOD1 mutations
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
BioCentury | Apr 20, 2017
Product R&D
Selectivity suite
How a Scripps team is finding RNA-binding small molecules
Items per page:
1 - 7 of 7